{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:40:58Z","timestamp":1770882058100,"version":"3.50.1"},"reference-count":108,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273191"],"award-info":[{"award-number":["82273191"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303732"],"award-info":[{"award-number":["82303732"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite multiple clinical trials, the benefits and safety of epidermal growth factor (EGF)\/EGF receptor (EGFR) vaccines in EGFR\u2010driven solid tumors remain unclear due to small sample sizes and heterogeneous study designs. This systematic review and meta\u2010analysis aimed to evaluate their efficacy and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted pairwise and single\u2010arm meta\u2010analyses following PRISMA guidelines (PROSPERO: CRD420251026774). Searches in PubMed, Embase, and Cochrane Library identified 26 trials (2701 participants). The primary endpoint was overall survival (OS), with secondary analyses of progression\u2010free survival (PFS), objective response rate (ORR), disease control rate (DCR), and treatment\u2010related adverse events (TRAEs). Statistical analyses were performed using R software, with fixed or random\u2010effects models per heterogeneity (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with best supportive care, vaccine monotherapy significantly improved long\u2010term OS in NSCLC and GBM (3\u2010year OR\u2009=\u20092.16, 5\u2010year OR\u2009=\u20093.20) and prolonged median OS in NSCLC (HR\u2009=\u20090.76). In single\u2010arm studies, NSCLC patients receiving vaccine monotherapy had a 1\u2010year OS of 64% (75% in first\u2010line maintenance), with an ORR of 2% and DCR of 31%. For GBM, vaccine combination therapy improved 3\u2010year OS (OR\u2009=\u20092.42) and 2\u2010year PFS (OR\u2009=\u20091.63) versus standard therapy. Single\u2010arm combination analyses showed an overall 1\u2010year OS of 84%, ORR of 42%, and DCR of 87%, while NSCLC first\u2010line combination achieved a 1\u2010year OS of 85% and DCR of 89%. Notably, EGFR\u2010mutant NSCLC patients had a pooled ORR of 65% and DCR of 98%. Common TRAEs were grade 1\u20132 (injection site reactions, fever, headache, and vomiting), and combination therapy had no new or severe toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>EGF\/EGFR vaccines may improve survival in EGFR\u2010driven solid tumors, particularly NSCLC and GBM. Monotherapy enables long\u2010term disease control, and combination therapy enhances efficacy without added toxicity, supporting further clinical validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>PROSPERO CRD420251026774<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71295","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:08:15Z","timestamp":1760069295000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of\n                    <scp>EGF<\/scp>\n                    \/\n                    <scp>EGFR<\/scp>\n                    Vaccines in\n                    <scp>EGFR<\/scp>\n                    \u2010Driven Solid Tumors: A Systematic Review and Meta\u2010Analysis of Controlled and Single\u2010Arm Studies"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7347-0519","authenticated-orcid":false,"given":"Fei","family":"Chen","sequence":"first","affiliation":[{"name":"Cancer Center The First Hospital of Jilin University  Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Bai","sequence":"additional","affiliation":[{"name":"Cancer Center The First Hospital of Jilin University  Changchun China"},{"name":"Department of Pathology Duke University School of Medicine  Durham North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6496-7550","authenticated-orcid":false,"given":"Jiuwei","family":"Cui","sequence":"additional","affiliation":[{"name":"Cancer Center The First Hospital of Jilin University  Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.22034\/apjcp.2017.18.1.3"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201006\u20100913"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/1878\u20100261.12155"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.04.002"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph13100273"},{"key":"e_1_2_11_7_1","unstructured":"E. G.Paiva B.Orr A.Azeredo A.Brand\u00e3o M. R.Teixeira andP.Paulo \u201cEGFR\u2010STAT3 Activation Provides a Therapeutic Rationale for Targeting Aggressive ETV1\u2010Positive Prostate Cancer Molecular Oncology \u201d(2025) https:\/\/doi.org\/10.1002\/1878\u20100261.70069."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2020.1727702"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.Can\u201016\u20101656"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2016.241"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416\u2010020\u201001052\u20108"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032651"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx702"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2021.5270"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105583"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2025.118146"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052042"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030459"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01249"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111736"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201019\u20102027"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15701"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.09.012"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103305"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.804212"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1005626"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.07.018"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000488408"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11091460"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.2174\/156800907780618310"},{"issue":"11","key":"e_1_2_11_31_1","first-page":"4247","article-title":"Epidermal Growth Factor Receptor vIII Peptide Vaccination Is Efficacious Against Established Intracerebral Tumors","volume":"9","author":"Heimberger A. B.","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.04.030"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00269"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201015\u20100855"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201018\u20101140"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.6963"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1287902"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.707"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.958043"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq157"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(17)30517\u2010x"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643\u2010025\u201002752\u2010z"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.11.5980"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou348"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.67189"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv532.38"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476\u20108518\u20109\u20107"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12865\u2010018\u20100249\u20109"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.5.2.2334"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg102"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.AM2025\u2010852"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.745699"},{"key":"e_1_2_11_54_1","first-page":"283","article-title":"Clinical Evaluation of Cimavax EGF in Schedule Vaccine\u2010Chemotherapyvaccine in the Treatment of Patients With Hormone\u2010Refractory Prostate Tumours. Preliminary Results","volume":"19","author":"Ills D.","year":"2010","journal-title":"VacciMonitor"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.12.014"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.1435"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy425.048"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31818fe167"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.823287"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.Mct\u201009\u20100124"},{"key":"e_1_2_11_61_1","unstructured":"J. P. T. T. J.Higgins J.Chandler M.Cumpston T.Li M. J.Page andV. A.Welch Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (Updated August 2024)."},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2528"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.11"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201007\u20101050"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1762465"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209153"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102021\u2010002531"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.3013"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1358841"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010020\u201001206\u20104"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010018\u20100792\u20109"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41417\u2010019\u20100155\u20101"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13244\u2010021\u201000968\u2010w"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102022\u2010004849"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(17)30074\u20108"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.36"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060\u2010020\u201003598\u20102"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262\u2010013\u20101405\u2010y"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.113346"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.812916"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010025\u201013764\u20102"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127605"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2024.102499"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.06.017"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1205984"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423\u2010025\u201001316\u20104"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16428"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.940288"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00263"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102751"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13262"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104601"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262\u2010018\u20102218\u20109"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci148546"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e15578"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698\u2010025\u201000886\u2010w"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.70011"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.3390\/life15020283"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41746\u2010024\u201001043\u20106"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.3390\/biochem5020005"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1054231"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1101\/2025.01.04.631301"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202412881"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajps.2024.100902"},{"key":"e_1_2_11_107_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.tps2677"},{"key":"e_1_2_11_108_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.AM2024\u2010CT126"},{"key":"e_1_2_11_109_1","unstructured":"M.Reid A Vaccine (CIMAvax\u2010EGF) for the Prevention of Lung Cancer Development or Recurrence. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04298606."}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T13:11:00Z","timestamp":1765285860000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":108,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/cam4.71295"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71295","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-05-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71295"}}